AbbVie Contract Manufacturing
Transforming Concepts into Products

As of today, two common challenges exist in the life sciences industry. The first pertains to unanticipated situations, stemming either from regulatory feedback or difficulties in technology transfer. These occurrences can cause projects to deviate from their projected trajectories. The second challenge concerns capacity constraints. The pandemic led to reduced throughput in contract manufacturing organizations (CMOs) due to heightened precautions surrounding COVID-19 in manufacturing facilities. In specific segments, such as fill-finish manufacturing, increased activity exacerbated the problem.

"We, at AbbVie Contract Manufacturing, are at the forefront of addressing these challenges, not just as a CMO but as a reliable partner for advancing pharmaceutical excellence and securing the continuous flow of medicine to patients, fortified by our profound expertise and foresight," says Jeffrey Tremain, Director of Business Development and Marketing at AbbVie Contract Manufacturing.

AbbVie collaborates with companies across the globe to develop, manufacture, and expand the reach of pharmaceutical products, ensuring their successful introduction into the market. It leverages 40 years of experience as a CMO to offer valuable insights on commercializing pharmaceutical products, with a focus on quality and regulatory compliance.

In the context of AbbVie Contract Manufacturing's philosophy, the essence of their approach is expressed through their tagline, or perhaps their brand line, referred to as "vision, expertise, success.

" The vision is intricately linked to their extensive experience and successful navigation through the commercialization process of numerous products spanning diverse technologies. AbbVie Contract Manufacturing possesses a profound vision and comprehension of the journey, guiding partners seamlessly from the clinical phase to full commercialization. This aspect is unequivocally a cornerstone of their identity, encompassing both vision and expertise.

Its operational strategy is rooted in flexibility. Unlike independent CMOs that aim for near-maximum capacity utilization, AbbVie intentionally does not exceed an 80 percent utilization threshold. This strategic decision is driven by the desire to accommodate fluctuations in demand or shifts in market dynamics. The overarching objective is to guarantee the fulfillment of all product supply requirements for both their clientele and, notably, for patients associated with AbbVie. The ultimate goal is centered on ensuring that the intended pharmaceutical products reach all patients, aligning with the primary mission and purpose of AbbVie Contract Manufacturing.

From a clinical manufacturing perspective, AbbVie's primary focus is on aligning clinical manufacturing with the commercial process. It aims to understand and mitigate any significant risks related to clinical manufacturing activities. This includes complying with regulations, time-to-market planning, required development studies to ensure the success of commercial production, validation, and maintaining a secure supply chain when transitioning from clinical to commercial production.

Its experience in scaling up, along with in-house research and development and manufacturing capabilities, enables the organization to efficiently anticipate and minimize these risks, simplifying the transition process. Particularly, for supply chain security, the method of serialization and aggregation for packaging allows it to help secure the supply chain for its partners.

The difference in AbbVie's approach translates primarily into time savings. It holds more experience in dealing with manufacturing hurdles, data transfer issues, regulatory obstacles, and quality concerns. Data and reports are essential before submitting an NDA or biologics license application (BLA), or the risks involved in seeking approval. By partnering with a CMO like AbbVie, a company can receive more informed guidance and get their product to the market faster.

AbbVie Contract Manufacturing's proficiency in achieving impactful outcomes is rooted in its systematic client engagement approach, typically initiated with a thorough examination of the client's priorities. The process is characterized by a meticulous exploration to gain a comprehensive understanding of the client's specific needs, the intricacies of their manufacturing requirements, and any unique elements that define their project. This structured methodology serves as a foundation for forging successful partnerships by ensuring a clear alignment between AbbVie's capabilities and the distinctive requirements of its clients.

Following this exchange, AbbVie proceeds to examine its technical capabilities to ensure compatibility with the client's specific needs. In the wake of these preliminary discussions, if mutual satisfaction prevails, it formalizes a confidentiality disclosure agreement (CDA) and ventures into more comprehensive discussions. Besides, during these preliminary interactions, it ensures its purposes are in harmony with the client's aspirations. This reciprocity is the linchpin of the company’s partnership, as technical compatibility alone may not suffice.

Culture plays a pivotal role in any organization, and at AbbVie, it stands as a central pillar. What distinguishes AbbVie's culture is its resounding dedication to patient centricity. The guiding principle here is that every decision and every action is undertaken with the patient's well-being at the forefront.